These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26762942)

  • 1. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.
    Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Zhao Y; Hamm B; Gebauer B; Lin M; Geschwind JF; Chapiro J
    Eur Radiol; 2016 Sep; 26(9):3243-52. PubMed ID: 26762942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
    Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
    Ghani MA; Fereydooni A; Chen E; Letzen B; Laage-Gaupp F; Nezami N; Deng Y; Gan G; Thakur V; Lin M; Papademetris X; Schernthaner RE; Huber S; Chapiro J; Hong K; Georgiades C
    Eur Radiol; 2021 Dec; 31(12):8858-8867. PubMed ID: 34061209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
    Borde T; Nezami N; Laage Gaupp F; Savic LJ; Taddei T; Jaffe A; Strazzabosco M; Lin M; Duran R; Georgiades C; Hong K; Chapiro J
    Radiology; 2022 Jul; 304(1):228-237. PubMed ID: 35412368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.
    Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF
    Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma response to transcatheter arterial chemoembolisation using automatically generated pre-therapeutic tumour volumes by a random forest-based segmentation protocol.
    Khalaf AM; Fuentes D; Morshid A; Kaseb AO; Hassan M; Hazle JD; Elsayes KM
    Clin Radiol; 2019 Dec; 74(12):974.e13-974.e20. PubMed ID: 31521326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
    Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
    Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
    Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study.
    Li M; Xin Y; Fu S; Liu Z; Li Y; Hu B; Chen S; Liang C; Lu L
    Medicine (Baltimore); 2016 Jan; 95(2):e2458. PubMed ID: 26765441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.
    Chapiro J; Wood LD; Lin M; Duran R; Cornish T; Lesage D; Charu V; Schernthaner R; Wang Z; Tacher V; Savic LJ; Kamel IR; Geschwind JF
    Radiology; 2014 Dec; 273(3):746-58. PubMed ID: 25028783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation.
    Najmi Varzaneh F; Pandey A; Aliyari Ghasabeh M; Shao N; Khoshpouri P; Pandey P; Zarghampour M; Fouladi D; Liddell R; Anders RA; Kamel IR
    Eur Radiol; 2018 Jul; 28(7):3032-3040. PubMed ID: 29383518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE.
    Hinrichs JB; Shin HO; Kaercher D; Hasdemir D; Murray T; Kaireit T; Lutat C; Vogel A; Meyer BC; Wacker FK; Rodt T
    Eur Radiol; 2016 Oct; 26(10):3447-55. PubMed ID: 26769666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Preoperative MRI-derived 3D Quantitative Tumor Arterial Burden in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.
    Peng G; Huang XY; Wang YN; Cao XJ; Zhou X
    Radiol Imaging Cancer; 2024 May; 6(3):e230167. PubMed ID: 38607280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-arm computed tomography parenchymal blood volume measurement in evaluation of hepatocellular carcinoma before transarterial chemoembolization with drug eluting beads.
    Syha R; Grözinger G; Grosse U; Maurer M; Zender L; Horger M; Nikolaou K; Ketelsen D
    Cancer Imaging; 2015 Dec; 15():22. PubMed ID: 26715200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
    Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
    World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Local Tumor Control and Survival Rates by Obtaining a 3D-Safety Margin in Superselective Transarterial Chemoembolization for Small Hepatocellular Carcinoma.
    Kattipatanapong T; Nishiofuku H; Tanaka T; Sato T; Masada T; Tatsumoto S; Matsumoto T; Kichikawa K
    Cardiovasc Intervent Radiol; 2020 Mar; 43(3):423-433. PubMed ID: 31720806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
    Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.